Another RCT tested the potential effects of canakinumab, an anti-inflammatory drug targeting interleukin-1β proven to prevent cardiovascular events, on fasting plasma glucose, HbA1c, and risk of type 2 diabetes in individuals with prediabetes, previous myocardial infarction, and CRP > 2 mg/L [50]. The gene discussed is CRP; the disease is type 2 diabetes mellitus.